Shantha Biotech Of India Entertains GSK As New Suitor
This article was originally published in PharmAsia News
India's Shantha Biotech has attracted another suitor, this time GlaxoSmithKline. GSK seeks a 51 percent stake in Shantha, whose recent negotiations with Sanofi Aventis for a similar deal fell apart. The shares GSK seeks are some of those owned by Merieux Alliance of France. Merieux bought a 60 percent stake in Shantha in 2006 and added another 20 percent recently. GSK seeks Shantha's vaccine business. (Click here for more
You may also be interested in...
Demand for tele-diagnostic tools has reached unprecedented levels during COVID-19, said Kees Wesdrop, Royal Philips’ chief business leader of precision diagnosis.
Transparency On COVID Vaccine Clinical Holds Needed, Sharfstein Says; US FDA Advisory Cmtes Offer Venue
Former acting Commissioner Josh Sharfstein argues that while agency officials have done a commendable job in overall communication on COVID vaccine development, more information is needed on the clinical holds.
Trump administration effort to reduce drug prices by curtailing agency program requiring new approvals for some old products undermines FDA’s role in policing the safety of prescription drugs, experts say.